Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BioVaxys Technology Corp. C.BIOV

Alternate Symbol(s):  BVAXF

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.


CSE:BIOV - Post by User

BioVaxys Technology Corp.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(13)
•••
Post by Magnum2on Dec 21, 2022 12:27pm
173 Views
Post# 35184910

Moneywagon, I thought you were a "quality Pumper"....

Moneywagon, I thought you were a "quality Pumper"....get this Dawg going already....

C:BIOV - BioVaxys Technology Corp. - https://biovaxys.com
Sym-X Bid - Ask Last Chg %Ch Vol $Vol #Tr Open-Hi-Lo Year Hi-Lo Last Tr News Delay
BIOV - C   59.5 0.115 · 0.13 6.0 0.12 -0.01 -7.7 120.7 14 25 0.13  0.13  0.12 0.27  0.085 11:57:49 Dec 20 15 min RT 2¢
CSE - C 59.5 0.115 · 0.13 6.0 0.12 -0.01 -7.7 110.7 13 20 0.13  0.13  0.12 0.27  0.085 11:57:49   15 min
NEO ATS - U   0.12 -0.01 -7.7 7.5 1 2 0.13  0.13  0.12   11:57:49   15 min
Omega - O   0.12 -0.01 -7.7 2.5 0 2 0.125  0.125  0.12   11:57:49   15 min
CXD - D   0.13     0.0   1        Jul 04   15 min

 

Recent Trades - Last 10 of 25
Time ET Ex Price Change Volume Buyer Seller Markers
11:57:49 U 0.12 -0.01 2,500 1 Anonymous 7 TD Sec K
11:57:49 O 0.12 -0.01 2,000 1 Anonymous 7 TD Sec K
11:57:49 C 0.12 -0.01 2,500 80 National Bank 7 TD Sec K
11:46:42 C 0.12 -0.01 500 79 CIBC 7 TD Sec K
11:46:42 C 0.12 -0.01 3,000 79 CIBC 7 TD Sec K
11:46:42 C 0.12 -0.01 5,000 79 CIBC 7 TD Sec K
11:46:26 C 0.12 -0.01 125 85 Scotia 80 National Bank E
11:46:26 C 0.12 -0.01 2,500 80 National Bank 7 TD Sec K
11:46:26 C 0.12 -0.01 10,500 85 Scotia 7 TD Sec K
11:46:26 C 0.12 -0.01 500 36 Latimer 7 TD Sec K

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities